Ring Therapeutics

Ring Therapeutics is a biotechnology company developing a new class of targeted medicines through its Vectorology™ platform. The company engineers vector conjugates designed to carry therapeutic payloads to specific cells and tissues, with the aim of expanding what drug development can achieve. Its approach draws on the diversity and natural properties of commensal viruses found in humans, including their presence across different tissues and their ability to evade immune responses. Ring is harnessing these characteristics to develop therapies with tissue and cellular targeting, flexible payload options, potency, and potential for repeat dosing.

The company’s platform combines vector-based delivery technology with a scalable, modular manufacturing approach. Ring says this may support medicines with broader therapeutic windows, reduced potential for resistance, simpler production, and new mechanisms or functions. Its work focuses on designing and developing vector conjugate therapies; the provided information does not identify marketed products or specific treatment areas. Based in Cambridge, Massachusetts, Ring Therapeutics is a Flagship Pioneering company.